Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Hayden

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|February 29, 2020
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMTDonal P McLornan, Vittoria Malpassuti, Anne Lippinkhof-Kozijn, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
American Journal of Hematology|June 21, 2021
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis RegistryJuan-Carlos Hernández-Boluda, Arturo Pereira, Nicolaus Kröger, et al.
Bone Marrow Transplantation|November 12, 2024
Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTKavita Raj, Diderik-Jan Eikema, Sarah Lawless, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 9, 2019
Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow TransplantationDonal McLornan, Richard Szydlo, Linda Koster, et al.
Bone Marrow Transplantation|February 2, 2021
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMTGiorgia Battipaglia, Katya Mauff, Lotus Wendel, et al.
The Lancet. Haematology|December 9, 2022
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMTNicola Polverelli, Juan Carlos Hernández-Boluda, Tomasz Czerw, et al.
ALTEX|November 5, 2015
Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicologySarah Gordon, Mardas Daneshian, Joke Bouwstra, et al.
American Journal of Hematology|October 16, 2020
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)Nicola Polverelli, Katya Mauff, Nicolaus Kröger, et al.
Blood|June 6, 2022
Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysisMarie Robin, Liesbeth C de Wreede, Eric Padron, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|February 29, 2020
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMTDonal P McLornan, Vittoria Malpassuti, Anne Lippinkhof-Kozijn, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
American Journal of Hematology|June 21, 2021
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis RegistryJuan-Carlos Hernández-Boluda, Arturo Pereira, Nicolaus Kröger, et al.
Bone Marrow Transplantation|November 12, 2024
Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTKavita Raj, Diderik-Jan Eikema, Sarah Lawless, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 9, 2019
Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow TransplantationDonal McLornan, Richard Szydlo, Linda Koster, et al.
Bone Marrow Transplantation|February 2, 2021
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMTGiorgia Battipaglia, Katya Mauff, Lotus Wendel, et al.
The Lancet. Haematology|December 9, 2022
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMTNicola Polverelli, Juan Carlos Hernández-Boluda, Tomasz Czerw, et al.
ALTEX|November 5, 2015
Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicologySarah Gordon, Mardas Daneshian, Joke Bouwstra, et al.
American Journal of Hematology|October 16, 2020
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)Nicola Polverelli, Katya Mauff, Nicolaus Kröger, et al.
Blood|June 6, 2022
Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysisMarie Robin, Liesbeth C de Wreede, Eric Padron, et al.
Pageof 8